Current position

Millennium Management LLC’s Vertex Pharmaceuticals (VRTX) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Millennium Management LLCVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2021Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares1.07MHighest verified quarter-end share count
Quarters reported14Verified quarters with shares above zero
What happened?

Millennium Management LLC first reported Vertex Pharmaceuticals in Q3 2021. The reported position was increased and reduced across later filings. Millennium Management LLC currently reports 468.41K shares. The latest verified filing showed: Bought 1,419.7% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 1,419.7% more+437.59K shares · 468.41K shares reported after the change
Filing context

Quarter-end price $496.73

Q4 2025
Bought 791.0% more+324.62K shares · 365.66K shares reported after the change
Filing context

Quarter-end price $453.36

Q2 2025
Sold the entire position−309.94K shares · No shares reported at quarter-end
Q1 2025
Sold 0.2% of the position−708 shares · 309.94K shares remained
Filing context

Quarter-end price $484.82

Q4 2024
Bought 95.0% more+151.35K shares · 310.64K shares reported after the change
Filing context

Quarter-end price $402.70

Q1 2024
Sold 49.5% of the position−317.93K shares · 324.82K shares remained
Filing context

Quarter-end price $418.01

Portfolio importance

How important is Vertex Pharmaceuticals in Millennium Management LLC’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.1%Q2 2026
Current rank#195of 5796 reported positions
Peak portfolio weight0.2%Q2 2023
Best historical rank#50Q2 2023
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$516.342026-09-23

Market context only; not an investor transaction price.

Latest filing quarter-end price$496.73Q2 2026

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

View Vertex Pharmaceuticals stock page →

This is a bounded selection from a 13F combination report. A portion is reported separately by another manager. The profile does not represent all investments, trades or performance. Quarters are reporting observations, not transaction dates.